This protocol evaluates the efficacy of combining pharmacologic treatments for smoking
cessation, entailing the use of the nicotine skin patch with the nicotinic antagonist
mecamylamine, with a specific behavioral therapy designed to inhibit the smoking urge.
Phase:
Phase 2
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development